![](https://webarchive.library.unt.edu/eot2008/20081010005425im_/http://www.nci.nih.gov/images/spacer.gif) |
¿Preguntas sobre el cáncer?
![](https://webarchive.library.unt.edu/eot2008/20081010005425im_/http://www.nci.nih.gov/images/spacer.gif)
|
1-800-422-6237
(1-800-4-CANCER)
|
![](https://webarchive.library.unt.edu/eot2008/20081010005425im_/http://www.nci.nih.gov/images/spacer.gif)
|
Llame de lunes a viernes de 9:00 a.m. a 4:30 p.m., hora local en Estados Unidos y sus territorios. |
|
![](https://webarchive.library.unt.edu/eot2008/20081010005425im_/http://www.nci.nih.gov/images/spacer.gif) |
|
![](https://webarchive.library.unt.edu/eot2008/20081010005425im_/http://www.nci.nih.gov/images/spacer.gif)
![](https://webarchive.library.unt.edu/eot2008/20081010005425im_/http://www.nci.nih.gov/images/spacer.gif)
| Anticuerpo monoclonal que se usa en el tratamiento de ciertos tipos de linfomas no Hodgkin. Cuando se administra el tositumomab junto con yodo I 131 tositumomab (una forma de tositumomab alterada químicamente por el agregado de yodo radiactivo), la combinación se llama régimen de Bexxar. |
![](https://webarchive.library.unt.edu/eot2008/20081010005425im_/http://www.nci.nih.gov/images/spacer.gif)
![](https://webarchive.library.unt.edu/eot2008/20081010005425im_/http://www.nci.nih.gov/images/gray_spacer.gif)
![](https://webarchive.library.unt.edu/eot2008/20081010005425im_/http://www.nci.nih.gov/images/spacer.gif)
|
![](https://webarchive.library.unt.edu/eot2008/20081010005425im_/http://www.nci.nih.gov/images/spacer.gif) |